Go offline with the Player FM app!
Is Mirtazapine Appropriate for the Elderly?
Manage episode 315247916 series 2931422
A recent study calls into question the safety of mirtazapine in the elderly, an antidepressant often recommended in the elderly for treatment of senile cachexia due to the medication’s appetite stimulation properties. This episode reviews the SYMBAD trial with guest Sarah Grady, PharmD.
Guest:
Sarah Grady, PharmD
Drake University
Redeem your CPE or CME credit here!
Need a membership?
References and resources: Banerjee S, High J, Stirling S, et al. Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. Lancet. 2021 Oct 23;398(10310):1487-1497. doi: 10.1016/S0140-6736(21)01210-1. PMID: 34688369; PMCID: PMC8546216.
Continuing Education Information:
Learning Objectives:
- Describe the results of the SYMBAD study and its implications in the care of geriatric patients
- Discuss the adverse effects found in the SYMBAD study
Dr. Sarah Grady reports no actual or potential conflicts of interest associated with this episode.
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-401-H01-P
Initial release date: 12/20/21
Expiration date: 12/20/22
Additional CPE & CME details can be found here (www.ceimpact.com/podcast)
296 episodes
Manage episode 315247916 series 2931422
A recent study calls into question the safety of mirtazapine in the elderly, an antidepressant often recommended in the elderly for treatment of senile cachexia due to the medication’s appetite stimulation properties. This episode reviews the SYMBAD trial with guest Sarah Grady, PharmD.
Guest:
Sarah Grady, PharmD
Drake University
Redeem your CPE or CME credit here!
Need a membership?
References and resources: Banerjee S, High J, Stirling S, et al. Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. Lancet. 2021 Oct 23;398(10310):1487-1497. doi: 10.1016/S0140-6736(21)01210-1. PMID: 34688369; PMCID: PMC8546216.
Continuing Education Information:
Learning Objectives:
- Describe the results of the SYMBAD study and its implications in the care of geriatric patients
- Discuss the adverse effects found in the SYMBAD study
Dr. Sarah Grady reports no actual or potential conflicts of interest associated with this episode.
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-401-H01-P
Initial release date: 12/20/21
Expiration date: 12/20/22
Additional CPE & CME details can be found here (www.ceimpact.com/podcast)
296 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.